How PET/MR Can Add Value for Children with Cancer

被引：14
作者：
Daldrup-Link H.E. [1 ,2 ]
机构：
[1] Department of Radiology, Lucile Packard Children’s Hospital, and Pediatric Molecular Imaging Program (@PedsMIPS) in the Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford University, 725 Welch Rd, Rm 1665, Stanfo
[2] Department of Pediatrics, Stanford University, Stanford, CA
来源：
Current Radiology Reports | / 5卷 / 3期
关键词：
Magnetic resonance; Pediatric cancer; Pediatric lymphoma; Pediatric sarcoma; PET/MR; Positron emission tomography;
D O I：
10.1007/s40134-017-0207-y
中图分类号：
学科分类号：
摘要：
Purpose of Review: To review how positron emission tomography/magnetic resonance (PET/MR) technology could add value for pediatric cancer patients. Recent Findings: Since many primary tumors in children are evaluated with MR imaging and metastases are detected with PET/computed tomography (CT), integrated PET/MR can be a time-efficient and convenient solution for pediatric cancer staging. 18 F-FDG PET/MR can assess primary tumors and the whole body in one imaging session, avoid repetitive anesthesia, and reduce radiation exposure compared to 18 F-FDG PET/CT. This article lists 10 action points, which might improve the clinical value of PET/MR for children with cancer. However, even if PET/MR proves valuable, it cannot enter mainstream applications if it is not accessible to the majority of pediatric cancer patients. Therefore, innovations are needed to make PET/MR scanners affordable and increase patient throughput. Summary: PET/MR offers opportunities for more efficient, accurate, and safe diagnoses of pediatric cancer patients. The impact on patient management and outcomes has to be substantiated by large-scale prospective clinical trials. © 2017, Springer Science+Business Media New York.
引用
收藏
相关论文
共 119 条
  • [1] Federman N., Feig S.A., PET/CT in evaluating pediatric malignancies: a clinician’s perspective, J Nucl Med Off Publ Soc Nucl Med., 48, 12, pp. 1920-1922, (2007)
  • [2] Tatsumi M., Miller J.H., Wahl R.L., <sup>18</sup> F-FDG PET/CT in evaluating non-CNS pediatric malignancies , J Nucl Med Off Publ Soc Nucl Med., 48, 12, pp. 1923-1931, (2007)
  • [3] Gerth H.U., Juergens K.U., Dirksen U., Gerss J., Schober O., Franzius C., Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors, J Nucl Med Off Publ Soc Nucl Med., 48, 12, pp. 1932-1939, (2007)
  • [4] Kleis M., Daldrup-Link H., Matthay K., Goldsby R., Lu Y., Schuster T., Et al., Diagnostic value of PET/CT for the staging and restaging of pediatric tumors, Eur J Nucl Med Mol Imaging, 36, 1, pp. 23-36, (2009)
  • [5] Uslu L., Donig J., Link M., Rosenberg J., Quon A., Daldrup-Link H.E., Value of <sup>18</sup> F-FDG PET and PET/CT for evaluation of pediatric malignancies , J Nucl Med, 56, 2, pp. 274-286, (2015)
  • [6] Punwani S., Taylor S.A., Bainbridge A., Prakash V., Bandula S., De Vita E., Et al., Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging, Radiology, 255, 1, pp. 182-190, (2010)
  • [7] Krohmer S., Sorge I., Krausse A., Kluge R., Bierbach U., Marwede D., Et al., Whole-body MRI for primary evaluation of malignant disease in children, Eur J Radiol, 74, 1, pp. 256-261, (2010)
  • [8] Kwee T.C., van Ufford H.M., Beek F.J., Takahara T., Uiterwaal C.S., Bierings M.B., Et al., Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography, Investig Radiol, 44, 10, pp. 683-690, (2009)
  • [9] Kwee T.C., Takahara T., Ochiai R., Katahira K., Van Cauteren M., Imai Y., Et al., Whole-body diffusion-weighted magnetic resonance imaging, Eur J Radiol, 70, 3, pp. 409-417, (2009)
  • [10] Klenk C., Gawande R., Uslu L., Khurana A., Qiu D., Quon A., Et al., Ionising radiation-free whole-body MRI versus <sup>(18)</sup> F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study , Lancet Oncol, 15, 3, pp. 275-285, (2014)
12345678910